Complete high-intensity focused ultrasound in prostate cancer: outcome from the @-Registry

被引：16

作者：

Blana, A. ^{[1
]}

Robertson, C. N. ^{[2
]}

Brown, S. C. W. ^{[3
]}

Chaussy, C. ^{[4
]}

Crouzet, S. ^{[5
]}

Gelet, A. ^{[5
]}

Conti, G. N. ^{[6
]}

Ganzer, R. ^{[7
]}

Pasticier, G. ^{[8
]}

Thuroff, S. ^{[4
]}

Ward, J. F. ^{[9
]}

机构：

[1] Fuerth Hosp, Dept Urol, D-90766 Furth, Germany

[2] Duke Univ, Div Urol, Durham, NC USA

[3] Stepping Hill Hosp, Dept Urol, Stockport SK2 7JE, Lancs, England

[4] Harlaching Hosp, Dept Urol, Munich, Germany

[5] Hop Edouard Herriot, Dept Urol, Lyon, France

[6] St Anna Hosp, Dept Urol, Como, Italy

[7] Univ Regensburg, Dept Urol, Regensburg, Germany

[8] CHU Pellegrin, Dept Urol, Bordeaux, France

[9] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA

来源：

PROSTATE CANCER AND PROSTATIC DISEASES | 2012年 / 15卷 / 03期

关键词：

biochemical failure; biopsy; high-intensity focused ultrasound; PSA; BIOCHEMICAL FAILURE; TRANSRECTAL HIFU;

D O I：

10.1038/pcan.2012.10

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BACKGROUND: To analyze data on patients with localized prostate cancer who were treated with complete high-intensity focused ultrasound (HIFU) prospectively captured within a voluntary HIFU user database (@-Registry). METHODS: The @-Registry includes data from consecutive patients treated with Ablatherm (EDAP-TMS) HIFU at nine European Centres during the period 1994 and 2009. For this analysis, the data repository was reviewed for information on patients with localized prostate cancer (T1 - T2) treated with complete (whole-gland) HIFU on the basis of an anterior-posterior prostate height of <= 24 mm and a treated volume > 120% of the prostate volume. Patients were regularly followed with PSA measurement and biopsy. Biochemical failure was defined for this study as PSA nadir + 2 ng ml(-1) (Phoenix definition). Disease-free survival was based on a biopsy, retreatment and biochemical data. Patients were risk group-stratified using the D'Amico classification system. RESULTS: The median follow-up was 2.8 years for the 356 patients included in the analysis. The majority could be classified as either low (44.9%) or intermediate risk (39.6%); 14.6% patients were classified as high risk. The median (mean, s.d.) PSA nadir was 0.11 ng ml(-1) (0.78 and 3.6), achieved at a mean (s.d.) of 14.4 (11.6) weeks after HIFU. Follow-up biopsies on 226/356 (63.5%) patients revealed an overall negative biopsy rate of 80.5% (182/226); there was no statistically significant difference in positive biopsy rate by risk group-stratification. Actuarial freedom from biochemical recurrence at 5 and 7 years according to the Phoenix definition was 85% and 79%, respectively. Disease-free progression rates at 5 and 7 years were 64% and 54%, respectively. CONCLUSIONS: Whole-gland prostate HIFU as primary monotherapy for localized prostate cancer achieves a recurrence-free survival in short-term analysis as assessed by prostate biopsy and serum PSA endpoints in a majority of patients.

引用

页码：256 / 259

页数：4

共 10 条

[1] First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer [J].